Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 August 1995Website:
http://windtreetx.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 26 Jun 2024 22:56:38 GMTDividend
Analysts recommendations
Institutional Ownership
WINT Latest News
WARRINGTON, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming ThinkEquity Conference on Thursday, October 19, 2023 at 4:30pm ET. Windtree management will also be hosting 1x1 meetings with investors at the event.
Windtree Therapeutics (NASDAQ: WINT ) stock is falling on Thursday after the company announced the departure of its Chairman of the Board of Directors. James Huang is departing from Windtree Therapeutics for a couple of reasons.
On an otherwise bearish day in the markets, many investors may be looking for some good news. For those on such a search, taking a look at some of the big movers in the biotech sector is a great place to start.
What type of business is Windtree Therapeutics?
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
What sector is Windtree Therapeutics in?
Windtree Therapeutics is in the Healthcare sector
What industry is Windtree Therapeutics in?
Windtree Therapeutics is in the Biotechnology industry
What country is Windtree Therapeutics from?
Windtree Therapeutics is headquartered in United States
When did Windtree Therapeutics go public?
Windtree Therapeutics initial public offering (IPO) was on 07 August 1995
What is Windtree Therapeutics website?
https://windtreetx.com
Is Windtree Therapeutics in the S&P 500?
No, Windtree Therapeutics is not included in the S&P 500 index
Is Windtree Therapeutics in the NASDAQ 100?
No, Windtree Therapeutics is not included in the NASDAQ 100 index
Is Windtree Therapeutics in the Dow Jones?
No, Windtree Therapeutics is not included in the Dow Jones index
When does Windtree Therapeutics report earnings?
The next expected earnings date for Windtree Therapeutics is 07 August 2024